An evaluation of enasidenib for the treatment of acute myeloid leukemia

References

• Song X, Peng Y, Wang X, et al. Incidence, survival, and risk factors for adults with acute myeloid leukemia not otherwise specified and acute myeloid leukemia with recurrent genetic abnormalities: analysis of the Surveillance, Epidemiology, and End Results (SEER) database, 2001–2013. Acta Haematol. 2018;139:115–127.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults : 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–448.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidlines in oncology. J Natl Compr Cancer Netw. 2019;17:721–749.
   Web of Science ®Google Scholar
• Thol F, Schlenk RF, Heuser M, et al. How I treat refractory and early relapsed acute myeloid leukemia. Blood. 2015;126:319–327.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Müller-Tidow C, Benner A, et al. Relapsed/refractory acute myeloid leukemia: any progress? Curr Opin Oncol. 2017;29:467–473.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the world health organization classi fi cation of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2406.
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12–27.
   PubMed Web of Science ®Google Scholar
• Sun Y, Chen B-R, Deshpande A. Epigenetic regulators in the development, maintenance, and therapeutic targeting of acute myeloid leukemia. Front Oncol. 2018;8:41.
   PubMed Web of Science ®Google Scholar
• Ramos F, Pleyer L, Maurillo L, et al. Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction. Leuk Res. 2015;39:1–11.
   Web of Science ®Google Scholar
• Fathi AT, Chen YB. The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia. Eur J Haematol. 2017;98:330–336.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Müller-Tidow C, Benner A, et al. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leuk Res. 2018;10:39–49.
   Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–464.
   PubMed Web of Science ®Google Scholar
• Bergua JM, Montesinos P, Martinez-Cuadrón D, et al. A prognostic model for survival after salvage treatment with FLAG-Ida +/− gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol. 2016;174:700–710.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation is safe, effective, and leads to mrd-negative complete remissions. Blood. 2018;132:560.
   Web of Science ®Google Scholar
• FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia. [cited 2018 Jul]. FDA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211192s000lbl.pdf
   Google Scholar
• FDA granted regular approval to enasidenib for the treatment of relapsed or refractory AML. FDA. [cited 2018 Jan]. Available from: www.accessdata.fda.gov/drugsatfda_docs/-label/2017/209606s000lbl.pdf
   Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–1812.
   PubMed Web of Science ®Google Scholar
• Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17:72.
   PubMed Web of Science ®Google Scholar
• Goyal L, Govindan A, Sheth RA, et al. Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma. Oncologist. 2015;20:1019–1027.
   PubMed Web of Science ®Google Scholar
• Arai M, Nobusawa S, Ikota H, et al. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma. Brain Tumor Pathol. 2012;29:201–206.
   PubMed Web of Science ®Google Scholar
• Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol. 2011;224:334–343.
   PubMed Web of Science ®Google Scholar
• Kosmider O, Gelsi-Boyer V, Slama L, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia. 2010;24:1094–1096.
   PubMed Web of Science ®Google Scholar
• Thol F, Weissinger EM, Krauter J, et al. IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica. 2010;95:1668–1674.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Jimma T, Sulai NH, et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia. 2012;26:475–480.
   PubMed Web of Science ®Google Scholar
• Chou WC, Peng KY, Lei WC, et al. Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission. Leukemia. 2012;26:527–529.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010;18:553–567.
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–2221.
   PubMed Web of Science ®Google Scholar
• McKerrell T, Park N, Moreno T, et al. Leukemia-associated somatic mutations drive distinct patterns of age-related clonal hemopoiesis. Cell Rep. 2015;10:1239–1245.
   PubMed Web of Science ®Google Scholar
• Xie M, Lu C, Wang J, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med. 2014;20:1472–1478.
   PubMed Web of Science ®Google Scholar
• Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–234.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Maharry K, Wu Y-Z, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2010;28:2348–2355.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Stein AS, Fathi AT, et al. Mutant isocitrate dehydrogenase (mIDH) inhibitors, enasidenib or ivosidenib, in combination with azacitidine (AZA): preliminary results of a phase 1b/2 study in patients with newly diagnosed acute myeloid leukemia (AML). Blood. 2017;130:639.
   Web of Science ®Google Scholar
• Montalban-Bravo G, DiNardo CD. The role of IDH mutations in acute myeloid leukemia. Futur Oncol. 2018;14:979–993.
   PubMed Web of Science ®Google Scholar
• Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol. 2010;28:3636–3643.
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Fathi AT, DiNardo CD, et al. Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia. 2017;31:272–281.
   PubMed Web of Science ®Google Scholar
• Platt MY, Fathi AT, Borger DR, et al. Detection of dual IDH1 and IDH2 mutations by targeted next-generation sequencing in acute myeloid leukemia and myelodysplastic syndromes. J Mol Diagn. 2015;17:661–668.
   PubMedGoogle Scholar
• Patel JP, Gönen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–1089.
   PubMed Web of Science ®Google Scholar
• Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116:2122–2126.
   PubMed Web of Science ®Google Scholar
• Xu Q, Li Y, Lv N, et al. Correlation between isocitrate dehydrogenase gene aberrations and prognosis of patients with acute myeloid leukemia: a systematic review and meta-analysis. Clin Cancer Res. 2017;23:4511–4522.
   PubMed Web of Science ®Google Scholar
• Boddu P, Takahashi K, Pemmaraju N, et al. Influence of IDH on FLT3-ITD status in newly diagnosed AML. Leukemia. 2017;31:2526–2529.
   PubMed Web of Science ®Google Scholar
• Brunner AM, Neuberg DS, Wander SA, et al. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. 2019;125:541–549.
   PubMed Web of Science ®Google Scholar
• Wang F, Travins J, DeLaBarre B, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340:622–626. (80-.).
   PubMed Web of Science ®Google Scholar
• Kernytsky A, Wang F, Hansen E, et al. IDH2 mutation-induced histone and DNA hypermethylation is progressively reversed by small-molecule inhibition. Blood. 2015;125:296–303.
   PubMed Web of Science ®Google Scholar
• Yen K, Travins J, Wang F, et al. AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations. Cancer Discov. 2017;7:478–493.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722–731.
   PubMed Web of Science ®Google Scholar
• Galeotti J, Coombs CC. Enasidenib-induced eosinophilic differentiation in a patient with acute myeloid leukaemia with IDH2 and U2AF1 mutations. Br J Haematol. 2019;184:496.
   PubMed Web of Science ®Google Scholar
• Shih AH, Shank K, Nazir A, et al. Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2- and TET2-mutant acute myeloid leukemia. Cancer Discov. 2017;7:494–505.
   PubMed Web of Science ®Google Scholar
• Celgene Corporation. IDHIFA (enasidenib) tablets: US prescribing informations. 2017. [Internet]. [cited 2017 Aug]. Available from: https://media.celgene.com/content/uploads/idhifa-pi.pdf
   Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019;133:676–687.
   PubMed Web of Science ®Google Scholar
• Amatangelo MD, Quek L, Shih A, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130:732–741.
   PubMed Web of Science ®Google Scholar
• IDH2 inhibition using enasidenib as maintenance therapy for IDH2-mutant myeloid neoplasms following allogeneic stem cell transplantation - full text view - clinicaltrials.gov [Internet]. [cited 2019 May 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT03515512
   Google Scholar
• An efficacy and safety study of AG-221 (CC-90007) versus conventional care regimens in older subjects with late stage acute myeloid leukemia harboring an isocitrate dehydrogenase 2 mutation - full text view - clinicaltrials.gov [Internet]. [cited 2019 May 21]. Available from: https://clinicaltrials.gov/ct2/show/NCT02577406
   Google Scholar
• Patel SA. Enasidenib-induced differentiation syndrome in IDH2 -mutant acute myeloid leukemia. JAMA Oncol. 2018;4:1110.
   PubMed Web of Science ®Google Scholar
• Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. Longo DL, editor. N Engl J Med. 2015;373: 1136–1152.
   PubMed Web of Science ®Google Scholar
• Bose P, Vachhani P, Cortes JE. Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat Options Oncol. 2017;18:17.
   Web of Science ®Google Scholar
• Meyers J, Yu Y, Kaye JA, et al. Medicare fee-for-service enrollees with primary acute myeloid leukemia: an analysis of treatment patterns, survival, and healthcare resource utilization and costs. Appl Health Econ Health Policy. 2013;11:275–286.
   PubMedGoogle Scholar
• Ferrara F, Lessi F, Vitagliano O, et al. Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia. Cancers (Basel). 2019;11.
   PubMed Web of Science ®Google Scholar
• Caino MC, Ghosh JC, Chae YC, et al. PI3K therapy reprograms mitochondrial trafficking to fuel tumor cell invasion. Proc Natl Acad Sci. 2015;112:8638–8643.
   PubMed Web of Science ®Google Scholar
• Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment [Internet]. [cited 2019 May 2]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/hematologic-malignancies-regulatory-considerations-use-minimal-residual-disease-development-drug-and
   Google Scholar
• Intlekofer AM, Shih AH, Wang B, et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018;559:125–129.
   PubMed Web of Science ®Google Scholar